Last reviewed · How we verify

NCT03682393: MitralPOCS

Post-operative Corticosteroid Treatment After Mitral Valve Surgery

Withdrawn Phase 2, PHASE3 Last updated 7 April 2022
What this trial tests

Phase 2, PHASE3 trial testing Hydrocortisone in Atrial Fibrillation. Withdrawn.

Timeline
1 January 2020
Primary endpoint
31 December 2022
31 December 2022

Quick facts

Lead sponsorKuopio University Hospital
PhasePhase 2, PHASE3
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposeprevention
Start date1 January 2020
Primary completion31 December 2022
Estimated completion31 December 2022
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Kuopio University Hospital

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to intestigate whether three days intravenous corticosteroid management prevent atrial fibrillations in adults after mitral valve surgery. Prospective double-blinded randmized international multicenter study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hydrocortisone

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Kuopio University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03682393.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing